ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Shionogi & Co., Ltd.

Business Summary

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2023 JPYUSD
Gross Profit356,580M2,631.24M
Operating income160,551M1,184.72M
Income before tax220,365M1,626.10M
Net income184,965M1,364.87M
Diluted EPS621.094.58
Dividends Per Share1350.99
Total Assets1,311.80B9,856.48M
Total liabilities188,658M1,417.52M
Total equity1,100.04B8,265.42M
Operating cash flow177,867M1,312.50M
Currency in JPYCurrency in USD

Historical Data

 Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Revenue 367,960M 333,371M 297,177M 335,138M 426,684M
Gross Profit 305,713M 270,117M 238,000M 272,411M 356,580M
Operating income 168,370M 130,609M 95,694M 111,480M 160,551M
Income before tax 174,043M 158,516M 143,018M 126,288M 220,365M
Net income 137,190M 122,193M 111,858M 114,185M 184,965M
EBITDA 187,074M 144,649M 110,403M 127,773M 177,716M
Diluted EPS 434.70 395.28 364.88 378.62 621.09
Dividends Per Share 94 103 108 115 135
Total Assets 938,540M 873,695M 998,992M 1,150.60B 1,311.80B
Total liabilities 125,125M 108,186M 134,156M 157,052M 188,658M
Total equity 808,774M 765,152M 846,108M 975,661M 1,100.04B
Operating cash flow 165,000M 131,940M 109,039M 102,068M 177,867M
 Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Revenue 3,318.10M 3,066.16M 2,802.03M 2,982.37M 3,148.55M
Gross Profit 2,756.78M 2,484.38M 2,244.06M 2,424.17M 2,631.24M
Operating income 1,518.28M 1,201.26M 902.28M 992.05M 1,184.72M
Income before tax 1,569.44M 1,457.94M 1,348.49M 1,123.83M 1,626.10M
Net income 1,237.11M 1,123.86M 1,054.69M 1,016.12M 1,364.87M
EBITDA 1,686.95M 1,330.40M 1,040.97M 1,137.04M 1,311.38M
Diluted EPS 3.92 3.63 3.44 3.36 4.58
Dividends Per Share 0.84 0.94 1.01 1.02 0.99
Total Assets 8,479.37M 8,093.14M 9,040.65M 9,479.72M 9,856.48M
Total liabilities 1,130.46M 1,002.13M 1,214.08M 1,293.94M 1,417.52M
Total equity 7,306.98M 7,087.69M 7,657.08M 8,038.40M 8,265.42M
Operating cash flow 1,487.89M 1,213.51M 1,028.11M 908.29M 1,312.50M

Valuation Measures

Mar 2023
Operating margin37.62%
Profit margin43.34%


  • Chairman, Chief Executive Officer & President: Isao Teshirogi
  • Manager-Accounting & Finance: Yuji Hosogai
  • Senior Executive Officer & GM-Research: Yasuetsu Imune
  • Senior Executive Officer, Head-R&D: John Keller
  • Executive Officer & GM-Reliability Guarantee: Takeshi Shiota


  • Sumitomo Life Insurance Co. (6.0%)
  • Nomura Asset Management Co., Ltd. (5.9%)
  • Shionogi & Co., Ltd. (3.8%)
  • BlackRock Fund Advisors (3.1%)
  • Sumitomo Mitsui Banking Pension Fund (3.0%)
  • The Vanguard Group, Inc. (3.0%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.9%)
  • Nikko Asset Management Co., Ltd. (2.9%)
  • Nippon Life Insurance Co. (2.7%)
  • Daiwa Asset Management Co. Ltd. (2.7%)

Contact Details

Related Companies

  • Shionogi Srl
  • Shionogi infectious Disease research Foundation
  • Shionogi Singapore Pte Ltd.
  • Shionogi Marketing Solutions Co., Ltd.
  • Shionogi Pharmacovigilance Center Co., Ltd.
  • Shionogi Business Partner Co., Ltd.
  • Shionogi Digital Science Co., Ltd
  • Shionogi Career Development Center Co., Ltd.
  • Shionogi TechnoAdvance Research Co., Ltd.
  • Shionogi BV
  • Shionogi Pharma Co., Ltd.
  • Shionogi Healthcare Co. Ltd.
  • Shionogi & Co., Ltd. /2 Subsidiaries/
  • Shionogi & Co. Restricted Stock Compensation Plan
  • Pionnier KK
  • Shionogi USA Holdings, Inc.
  • Beijing Shionogi Pharmaceutical Technology Ltd.
  • Shionogi Ltd.
  • Ezose Sciences, Inc.
  • Shionogi Inc.
  • Shionogi Institute for Medical Science
  • Aburahi Laboratories
  • Taiwan Shionogi & Co., Ltd.
  • Shionogi Pharma Chemicals Co., Ltd.
  • Shionogi General Service Co., Ltd.
  • Shionogi Bunseki Center KK
  • Shionogi Ireland Ltd.
  • Shionogi Engineering Service Co. Ltd.
  • UMN Pharma, Inc.
  • Shionogi Bioresearch Corp.


  • Nabriva Therapeutics Plc
  • Protara Therapeutics, Inc.
  • Vaxart, Inc.
  • Cocrystal Pharma Inc
  • TaiGen Biopharmaceuticals Holdings Limited
  • Trevi Therapeutics, Inc.
  • Spero Therapeutics, Inc.
  • Zynerba Pharmaceuticals Inc
  • BioCryst Pharmaceuticals, Inc.
  • Iterum Therapeutics plc
  • Atea Pharmaceuticals, Inc.
  • Terns Pharmaceuticals, Inc.
  • Acura Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Vir Biotechnology, Inc.
  • Cutia Therapeutics
  • Innoviva, Inc.
Last Updated on 21 Sep, 2023

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more